The Incidence and Outcomes of COVID-19 in IBD Patients: A Rapid Review and Meta-analysis

Aziz, Muhammad; Fatima, Rawish; Haghbin, Hossein; Lee‐Smith, Wade; Nawras, Ali

doi:10.1093/ibd/izaa170

Cited by 51 publications

(61 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anxiety subscale scores correspond to normal population (0-7) mild, (8-9) moderate (10)(11)(12)(13)(14) and severe symptoms (15)(16)(17)(18)(19). Similarly, stress subscale scores corresponded to normal population (0-14), mild (15)(16)(17)(18), moderate (19)(20)(21)(22)(23)(24)(25) or severe symptoms (26)(27)(28)(29)(30)(31)(32)(33). Significant depression, anxiety and/or stress in our study was defined as at least moderate DASS21 subscores for depression, anxiety and/or stress.…”

Section: Study Design and Study Populationmentioning

confidence: 99%

“…Respondents score each item from 0 to 3, and item scores are added together and multiplied by 2 for each domain to generate three subscale scores. Depression subscale scores corresponds to normal population (0-9), mild (10)(11)(12)(13), moderate (14)(15)(16)(17)(18)(19)(20) and severe symptoms (21)(22)(23)(24)(25)(26)(27). Anxiety subscale scores correspond to normal population (0-7) mild, (8-9) moderate (10)(11)(12)(13)(14) and severe symptoms (15)(16)(17)(18)(19).…”

Section: Study Design and Study Populationmentioning

confidence: 99%

“…[22][23][24] A meta-analysis of studies found a lower incidence of COVID-19 infection among IBD populations, when compared with incidence reported in general population studies. 25 This lower incidence may reflect higher precautions taken by patients with IBD on average compared with the general population. Nevertheless, the perception of increased susceptibility to COVID-19 was associated with significant depression, anxiety and stress in our study population.…”

Section: Open Accessmentioning

confidence: 99%

See 2 more Smart Citations

Depression, anxiety and stress among patients with inflammatory bowel disease during the COVID-19 pandemic: Australian national survey

Cheema

Mitrev

Hall³

et al. 2021

BMJ Open Gastroenterol

View full text Add to dashboard Cite

BackgroundThe global COVID-19 pandemic has impacted on the mental health of individuals, particularly those with chronic illnesses. We aimed to quantify stress, anxiety and depression among individuals with Inflammatory bowel disease (IBD) in Australia during the pandemic.MethodsAn electronic survey was made available to IBD patients Australia-wide from 17 June to 12 July 2020. Respondents with an underlying diagnosis of IBD and over 18 years of age were included. A validated questionnaire (Depression, Anxiety, Stress Score-21, DASS21) was used to assess depression, anxiety and stress. Data on potential predictors of depression, anxiety and stress were collected.Results352 participated in the survey across Australia. 60.5% of respondents fulfilled DASS criteria for at least moderate depression, anxiety or stress. 45% reported a pre-existing diagnosis of depression and/or anxiety. Over 2/3 of these respondents reported worsening of their pre-existing depression/anxiety due to the current pandemic. Of those without a pre-existing diagnosis of anxiety or depression, high rates of at least moderate to severe depression (34.9%), anxiety (32.0%) and stress (29.7%) were noted. Younger age (OR 0.96, 95% CI 0.94 to 0.98, p<0.001), lack of access to an IBD nurse (OR 1.81, 95% CI 1.03 to 3.19, p=0.04) and lack of education on reducing infection risk (OR 1.99, 95% CI 1.13 to 3.50, p=0.017) were associated with significant stress, anxiety and/or depression.ConclusionHigh prevalence of undiagnosed depression, anxiety and stress was identified among respondents. Improved access to IBD nurse support and greater attention to education are modifiable factors that may reduce depression, anxiety and/or stress among patients with IBD during the pandemic.

show abstract

Section: Study Design and Study Populationmentioning

confidence: 99%

Section: Study Design and Study Populationmentioning

confidence: 99%

Section: Open Accessmentioning

confidence: 99%

See 1 more Smart Citation

Depression, anxiety and stress among patients with inflammatory bowel disease during the COVID-19 pandemic: Australian national survey

Cheema

Mitrev

Hall³

et al. 2021

BMJ Open Gastroenterol

View full text Add to dashboard Cite

show abstract

“…As the COVID-19 rapidly spread, both physicians and patients have been deeply concerned about the possible increased risk of COVID-19 infection in patients with IBD. In a study of 9177 IBD patients in USA, 32 were reported to have confirmed COVID-19 (0.3%, 95% CI 0.1–0.5%) [ 132 ]. Despite a few studies found that patients with IBD more likely to be affected by the COVID-19 pandemic [ 133 , 134 ].…”

Section: Sars-cov-2 and Autoimmune Diseasesmentioning

confidence: 99%

COVID-19 illness and autoimmune diseases: recent insights

Liu

Yin

et al. 2021

Inflamm. Res.

View full text Add to dashboard Cite

Background The aim of this review is to explore whether patients with autoimmune diseases (AIDs) were at high risk of infection during the COVID-19 epidemic and how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic affected immune system. Methods A systematic literature search was performed using the foreign databases (NCBI, web of science, EBSCO, ELSEVIER ScienceDirect) and Chinese databases (WanFang, CNKI (China National Knowledge Infrastructure), VIP, CBM) to locate all relevant publications (up to January 10, 2021). The search strategies used Medical Search Headings (MeSH) headings and keywords for “COVID-19” or “SARS-CoV-2” or “coronavirus” and “autoimmune disease”. Results This review evaluates the effect of SARS-CoV-2 on the immune system through ACE-2 receptor binding as the main pathway for cell attachment and invasion. It is speculated that SARS-COV-2 infection can activate lymphocytes and inflammatory response, which may play a role in the clinical onset of AIDs and also patients were treated with immunomodulatory drugs during COVID-19 outbreak. Preliminary studies suggested that the risk of developing severe forms of COVID-19 in patients with AIDs treated with immunomodulators or biologics might not increase. A large number of samples are needed for further verification, leading to an excessive immune response to external stimuli. Conclusion The relationship between autoimmune diseases and SARS-CoV-2 infection is complex. During the COVID-19 epidemic, individualized interventions for AIDs should be provided such as Internet-based service.

show abstract

“…3). The protection against COVID-19 might be due to the ongoing therapy of IBD and it should not be stopped (Aziz et al, 2020). Therefore, priority must be given to the maintenance of IBD remission, as risk of flares outweighs the probability of contracting SARS-CoV-2 infection.…”

Section: Recommendatory Note On Ibd During Covid-19mentioning

confidence: 99%

Immunological co-ordination between gut and lungs in SARS-CoV-2 infection

2020

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a major pandemic called coronavirus disease 2019 (COVID-19) that has created unprecedented global health emergencies, and emerged as a serious threat due to its strong ability for human-to-human transmission. The reports indicate the ability of SARS-CoV-2 to affect almost any organ due to the presence of a receptor known as angiotensin converting enzyme 2 (ACE2) across the body. ACE2 receptor is majorly expressed in the brush border of gut enterocytes along with the ciliated cells and alveolar epithelial type II cells in the lungs. The amino acid transport function of ACE2 has been linked to gut microbial ecology in gastrointestinal (GI) tract, thereby suggesting that COVID-19 may, to some level, be linked to the enteric microbiota. The significant number of COVID-19 patients shows extra-pulmonary symptoms in the GI tract. Many subsequent studies revealed viral RNA of SARS-CoV-2 in fecal samples of COVID-19 patients. This presents a new challenge in the diagnosis and control of COVID-19 infection with a caution for proper sanitation and hygiene. Here, we aim to discuss the immunological coordination between gut and lungs that facilitates SARS-CoV-2 to infect and multiply in the inflammatory bowel disease (IBD) and non-IBD patients.

show abstract

The Incidence and Outcomes of COVID-19 in IBD Patients: A Rapid Review and Meta-analysis

Cited by 51 publications

References 4 publications

Depression, anxiety and stress among patients with inflammatory bowel disease during the COVID-19 pandemic: Australian national survey

Depression, anxiety and stress among patients with inflammatory bowel disease during the COVID-19 pandemic: Australian national survey

COVID-19 illness and autoimmune diseases: recent insights

Immunological co-ordination between gut and lungs in SARS-CoV-2 infection

Contact Info

Product

Resources

About